ETERNAL Blend (GHK-Cu / BPC-157 / TB-500 / Epithalon): What It Is, Where to Get It Prescribed, and What It Costs

ETERNAL is not a single molecule. It is four independently studied peptides — GHK-Cu, BPC-157, TB-500 and epithalon — dissolved together in one sterile multi-dose vial by a compounding pharmacy. Each has its own research literature, its own described mechanism and its own regulatory file at the FDA. The name is a brand name for the combination; it does not appear in any journal. That shapes everything on this page: "does ETERNAL work" has to be broken into four questions, because the combination itself has never been studied as a combination.

Three of the components — GHK-Cu, BPC-157 and TB-500 — are the same repair trio found in GLOW and KLOW. The fourth is what makes ETERNAL different. Epithalon has no tissue-repair literature; it comes from a separate Russian line of gerontology research on pineal peptides, telomerase and circadian rhythm. The rationale prescribers give is that someone whose goal is ageing well — skin, connective tissue, sleep rhythm — is asking a broader question than someone with a sore tendon, and the fourth slot is filled accordingly.

The proportions are worth noticing. GHK-Cu is 50 of the 80 mg in the vial, so by mass ETERNAL is mostly a GHK-Cu preparation with three smaller components. The ratio is fixed by the pharmacy's formulation and cannot be adjusted per component, which is the genuine trade-off of any blend.

It is not an anti-ageing drug in any established sense; no component is approved for any indication. It is not a hormone, a steroid or a growth-hormone secretagogue. It is not a painkiller. It is not a treatment for a structural problem: a full-thickness tendon rupture, a displaced fracture or a locking joint is a surgical or imaging question. And it is not a sleep medication: the epithalon circadian work is about melatonin rhythm in aged subjects, not sedation.

GHK-Cu is a tripeptide — glycine, histidine, lysine — that binds copper with high affinity. It occurs naturally in human plasma, where its concentration is reported to decline with age. The copper-carrying role is the basis for most of its described effects, because collagen cross-linking, elastin formation and several antioxidant enzymes are copper-dependent.

In cell and animal work, and in reviews in Biomed Research International (2015) and the International Journal of Molecular Sciences (2018), GHK-Cu is described as increasing synthesis of collagen, elastin, proteoglycans and glycosaminoglycans, and as shifting the balance between matrix metalloproteinases, which break tissue down, and their inhibitors. Gene-expression work reports effects across a large number of genes rather than one pathway. It is also described as supporting angiogenesis and as having antioxidant and anti-inflammatory activity in those models. A fuller treatment is on the GHK-Cu page.

BPC-157 is a fifteen-amino-acid partial sequence of a protein originally isolated from human gastric juice. Animal work describes it activating the VEGFR2 receptor and downstream nitric-oxide signalling, which is the axis the body uses to grow new blood vessels into healing tissue. A 2014 paper in Molecules reported that BPC-157 increased growth hormone receptor expression in cultured tendon fibroblasts and activated the FAK–paxillin pathway that governs cell attachment and migration. The receptor finding is often misread: it describes making those cells more responsive to growth hormone already present, not raising growth hormone.

Separately, the largest body of BPC-157 research concerns protection of the gastrointestinal lining in animal models, which is where the compound was first identified. A fuller treatment is on the BPC-157 page.

TB-500 is a synthetic peptide reproducing the actin-binding segment of thymosin beta-4, a 43-amino-acid protein that is one of the most abundant inside many human cells. Thymosin beta-4's primary described function is binding actin monomers, the protein that gives a cell its shape and lets it move.

The consequence described in the research is cell migration: repair cells moving into a wound. A 1999 paper in the Journal of Investigative Dermatology reported faster wound closure and increased cell migration with thymosin beta-4 in rats and in cultured human cells, and a 2012 review in Expert Opinion on Biological Therapy summarises the wider literature. One point of precision: most of that literature concerns the full-length protein. TB-500, the fragment, is assumed to share the actin-binding mechanism; the direct evidence for the fragment itself is much thinner. A fuller treatment is on the TB-500 page.

Epithalon is a synthetic tetrapeptide — alanine, glutamate, aspartate, glycine — designed in St Petersburg in the 1990s to reproduce the activity of epithalamin, a peptide extract of the pineal gland that the same group had studied since the 1970s. Almost all of the literature comes from that group, led by Vladimir Khavinson, which is the first thing to know about it.

Two mechanisms are described. The first is telomerase: a 2003 paper in the Bulletin of Experimental Biology and Medicine reported that epithalon induced telomerase activity and telomere elongation in cultured human somatic cells, which otherwise have the enzyme switched off. That is a cell-culture finding; it has not been shown to occur in a living person. The second is the pineal gland and melatonin: animal work describes epithalon and epithalamin restoring the night-time melatonin peak in aged monkeys and rats, and the same group reported epithalamin normalising the circadian rhythm of melatonin production in elderly people. A fuller treatment is on the epithalon page.

The map below is the clinical rationale for the blend. It is a rationale, not a finding — no study has confirmed that the four act together when injected together.

GHK-Cu has the deepest literature of the four and is the only repair component with human studies of any size. The human work is mostly small studies of topical GHK-Cu on facial skin — reporting changes in firmness, fine lines and elasticity — and observational wound-healing reports, summarised in the 2015 and 2018 reviews above. None of the human studies used the injectable form.

This rests on BPC-157 and, by extension from thymosin beta-4, on TB-500. A 2003 paper in the Journal of Orthopaedic Research examined transected Achilles tendon in rats and reported faster reattachment and better functional recovery in treated animals. Animal models of muscle crush injury report faster functional recovery. For TB-500, the tendon and muscle case is inferred from the full-length protein's wound-healing work rather than shown directly.

This is epithalon's territory and it needs careful reading. The telomerase finding is from cultured cells; nobody has measured telomere length in a person taking epithalon. In female SHR mice, a 2003 paper in Biogerontology reported that epithalon slowed several biomarkers of ageing and reduced spontaneous tumour incidence, without extending maximum lifespan; a 2002 paper in the Bulletin of Experimental Biology and Medicine reported similar findings in a breast-cancer-prone strain. The human work concerns epithalamin, the parent pineal extract, rather than the synthetic tetrapeptide: a 2004 report in the same Bulletin described it normalising the night-time melatonin rhythm in elderly people, and a 2006 paper described a long-term follow-up of elderly subjects with "accelerated ageing" in which epithalamin courses were associated with lower mortality than controls. Those studies are small, from a single group, and not blinded randomised trials. The honest framing is "described in cell and animal work and in small Russian clinical reports," not "proven to slow ageing."

This is the honest part, and the part worth understanding before starting.

There are no randomised controlled trials of ETERNAL, or of any four-peptide combination of these components, in humans. The blend has never been studied as a blend. Evidence is per component, and it is uneven:

• GHK-Cu has small human studies, mostly of topical application to skin. There are no randomised controlled trials of injectable GHK-Cu.
• BPC-157 has early-phase human work for inflammatory bowel indications and substantial prescribing experience. There are no large randomised controlled trials in humans, and none for tendon or soft-tissue injury.
• TB-500 has no randomised human trials. The full-length thymosin beta-4 protein has been studied in early-phase human trials for chronic dermal wounds and corneal conditions, but those used the whole protein, not the fragment.
• Epithalon has no randomised controlled trials. Its human data is a handful of small studies of the parent extract epithalamin in elderly Russian patients, from one research group, none independently replicated.

Much of medicine rests on mechanism plus clinical experience, and that is the basis physicians prescribe ETERNAL on. But the accurate framing is "described in preclinical research and used clinically," not "proven in people."

• That four peptides together do more than any one alone. No study has compared the blend with its components.
• That epithalon lengthens telomeres, slows ageing or extends life in humans. The telomerase work is in cultured cells; the lifespan work is in mice.
• An effect size for any indication, because those trials have not been run.
• A timeline in humans. Timelines given by prescribers are clinical experience, not trial endpoints.
• Long-term safety over years of continuous use, which is part of why a physician reviews each refill.
• Efficacy for any condition as an FDA-approved treatment. Neither ETERNAL nor any component is approved for anything.

From 2023 to early 2026 all four components sat in Category 2 of the FDA's 503A bulk drug substances list, the category for substances flagged as presenting significant safety risks. On 15 April 2026 the FDA announced the removal of twelve peptides from Category 2, effective within seven days, and BPC-157, TB-500, epitalon and injectable GHK-Cu were all among them. The non-injectable form of GHK-Cu, which had sat in Category 1, was removed from that list at the same time.

Removal from Category 2 lifts the safety-risk designation. It does not, by itself, place a substance on the positive 503A Bulks List; that requires an advisory committee review and a final FDA determination.

On 23 July 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8–6, with one abstention in each case, to recommend adding BPC-157 and TB-500 — each as the free base and the acetate — to the 503A Bulks List. On 24 July 2026 the committee voted 7–4, with one abstention, to recommend adding epitalon, which had been nominated for insomnia. FDA's own scientists had recommended against inclusion for each, citing insufficient safety, efficacy and characterisation data; the committee weighed the presentations and voted the other way.

A committee vote is a recommendation, not a decision. The FDA issues its own determination through notice-and-comment rulemaking, and that determination is still pending as of September 2026.

GHK-Cu was not on the July agenda. The FDA has said the committee will consider it, along with several other April removals, at a meeting to be held before the end of February 2027. Until then it is where the other three were between April and July: no longer flagged, not yet reviewed for the positive list.

None of the four components is restricted; three have been formally recommended for the positive list and await final FDA action; the fourth is scheduled for review. None is an FDA-approved drug product, and compounded medications never are — they are prepared by a licensed pharmacy to a physician's prescription, not approved as manufactured products.

Most people notice little or nothing. Injection-site tenderness is the most commonly reported observation. Some describe sleeping more regularly, which prescribers attribute to the epithalon component; noticing nothing in this window is normal and is not a sign the course is not working.

This is where prescribers most often describe a reduced background ache in a problem area and, for those tracking skin, a sense of better hydration. It is the window one vial covers on a weekday schedule.

Where tissue-level change happens, this is where it would be expected to show, based on the animal timelines for the tendon and soft-tissue work. Skin turnover is slow; texture and tone changes, where they occur, are described as a two-month-plus proposition. It typically takes a second vial to reach.

Nothing about cellular ageing is something you will feel, and there is no marker on a blood panel that ETERNAL is expected to move. Anyone who tells you they can see telomeres lengthening on a course is guessing. After a course there is no withdrawal and no rebound described for any component; whether any benefit persists depends on whether the underlying tissue actually changed.

The directions are written in millilitres and in insulin-syringe units because that is what you can actually read off the barrel. 0.25 mL is 25 units on a U-100 syringe. You are not calculating anything — the number is printed on your medication. Because the four are in fixed proportion, every dose delivers the same split: 2.5 mg GHK-Cu, 0.5 mg BPC-157, 0.5 mg TB-500 and 0.5 mg epithalon; you cannot take more of one and less of another.

Subcutaneous means into the fat layer, not the muscle. Abdomen and thigh are the usual sites, rotated so the same spot is not used repeatedly. Some prescribers direct injection near an affected area; others do not, because the mechanisms described are systemic. Your directions will say.

20 doses at five per week is four weeks of weekday dosing, which is why refills run on a 28-day cycle. Weekends off is part of the schedule, not a missed dose. One vial per fill, always — not a stockpile.

Refrigerated, and it ships that way in insulated packaging with ice packs. Beyond-use dating runs from first puncture and is on the label; a multi-peptide vial is not something to keep past it.

The only difference is the fourth peptide. KLOW carries KPV, an anti-inflammatory fragment of alpha-MSH, in the slot ETERNAL gives to epithalon; the other three components and their amounts are identical. If persistent inflammation is the reason for a repair blend, KLOW is the closer match; if the interest is repair alongside sleep rhythm and cellular ageing, ETERNAL is. KLOW is also available as a Pen; ETERNAL is vial-only.

GLOW is the same three repair peptides with nothing added. It is the version to prefer when the goal is skin and soft tissue and nothing else, and a physician may reasonably choose it over ETERNAL for that reason.

Epithalon on its own is the way to take the pineal peptide without 70 mg of repair peptides alongside it, and is what a physician will usually suggest if sleep rhythm or the longevity research is the whole reason for the conversation. The blend makes sense when the repair trio was already going to be prescribed.